Review: Current status of the development of inhaled insulin

The most promising alternative route of insulin administration seems to be pulmonary delivery by inhalation. For a maximal rate of absorption insulin must be applied deep into the lung, i.e., into ...

[1]  S. Mudaliar,et al.  Inhaled insulin using the AERx Insulin Diabetes Management System in healthy and asthmatic subjects. , 2003, Diabetes care.

[2]  N Lotan,et al.  Large porous particles for pulmonary drug delivery. , 1997, Science.

[3]  L. Heinemann,et al.  Impact of particle size and aerosolization time on the metabolic effect of an inhaled insulin aerosol. , 2004, Diabetes technology & therapeutics.

[4]  L. Heinemann,et al.  Time–action Profile of Inhaled Insulin , 1997, Diabetic medicine : a journal of the British Diabetic Association.

[5]  A. Morice,et al.  Pulmonary vasodilation in the rat by insulin in vitro could indicate potential hazard for inhaled insulin , 2003, Diabetologia.

[6]  R. Gerber,et al.  Treatment satisfaction with inhaled insulin in patients with type 1 diabetes: a randomized controlled trial. , 2001, Diabetes care.

[7]  C. Saudek.  Future Developments in Insulin Delivery Systems , 1993, Diabetes Care.

[8]  Lawrence Blonde,et al.  Efficacy and safety of inhaled insulin (exubera) compared with subcutaneous insulin therapy in patients with type 2 diabetes: results of a 6-month, randomized, comparative trial. , 2004, Diabetes care.

[9]  T. Heise,et al.  Intrasubject variability of inhaled insulin in type 1 diabetes: a comparison with subcutaneous insulin. , 2004, Diabetes technology & therapeutics.

[10]  D. Wall.  Pulmonary Absorption of Peptides and Proteins , 1995 .

[11]  Nick Freemantle,et al.  Availability of inhaled insulin promotes greater perceived acceptance of insulin therapy in patients with type 2 diabetes. , 2005, Diabetes care.

[12]  J. Patton,et al.  Drug delivery via the respiratory tract. , 1994, Journal of aerosol medicine : the official journal of the International Society for Aerosols in Medicine.

[13]  W. Cefalu,et al.  Inhaled Human Insulin Treatment in Patients with Type 2 Diabetes Mellitus , 2001, Annals of Internal Medicine.

[14]  J. Skyler.  Efficacy and safety of inhaled insulin (Exubera^( !R)) compared to subcutaneous insulin therapy in an intensive insulin regimen in patients with Type 1 diabetes : results of a 6-month, randomized, comparative trials , 2002 .

[15]  L. Heinemann,et al.  Intra-individual variability of the metabolic effect of inhaled insulin together with an absorption enhancer. , 2000, Diabetes care.

[16]  W. Cefalu,et al.  Efficacy of inhaled human insulin in type 1 diabetes mellitus: a randomised proof-of-concept study , 2001, The Lancet.

[17]  T. Rönnemaa,et al.  Intensive therapy with inhaled insulin via the AERx insulin diabetes management system: a 12-week proof-of-concept trial in patients with type 2 diabetes. , 2004, Diabetes care.

[18]  A. Himmelmann,et al.  The impact of smoking on inhaled insulin. , 2003, Diabetes care.

[19]  M. Ellmerer,et al.  Dose-response relation of liquid aerosol inhaled insulin in Type I diabetic patients , 2001, Diabetologia.

[20]  L. Heinemann,et al.  Technosphere/Insulin--proof of concept study with a new insulin formulation for pulmonary delivery. , 2002, Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association.

[21]  L. Heinemann,et al.  Time-action profile of inhaled insulin in comparison with subcutaneously injected insulin lispro and regular human insulin. , 2005, Diabetes care.

[22]  A. Pfützner,et al.  Technosphere/Insulin--a new approach for effective delivery of human insulin via the pulmonary route. , 2002, Diabetes technology & therapeutics.